CT Resources, Inc.

Contact: Claude Tihon, PhD
Location: 11304 Bluestem Ln
Eden Prairie, MN 55347
Email: ctihon@comcast.net
Tel: 952.944.3749
Website: N/A

Company Profile

Industry Sector: Medical Devices

Company Overview: CT Resources is a small developmental company focusing on developing a platform technology to treat clinical conditions to improve quality of life of the sufferers. These include major clinical conditions such as acid reflux, urinary incontinence, bowel incontinence, and others. The Company is backed by an experienced management team skilled in developing medical devices to the market in Fortune 100 companies and entrepreneurial organizations.

Target Market(s): The first product, Ω-Cuff, is to treat acid reflux (GERD) and targets gastroenterologists and GI surgeons, as well as patients and third party payers.

Key Value Drivers

Technology*: The platform technology is a simple device, designed to help the body to control flow of material through its biological tubes. The device aids the body's natural physiology to make the condition better.

Competitive Advantage: GERD has traditionally been treated by extremely invasive surgery with significant physiological perturbations. Ω-Cuff represents a simple, easy and safe alternative.

Plan & Strategy: CT Resources plans to develop the product through clinical studies and FDA market approval. The Company intends to partner with larger medical device companies to better address this huge market potential.

Management

Leadership: Claude Tihon, PhD

Scientific Advisory Board: We are fortunate to have a world renowned gastroenterologist, Dr. Bob Ganz and experienced surgeons Dr. Dan Dunn and Dr. Jim Andrisevic as our medical advisors. Because they all are very familiar with Linx, the latest GERD treatment device and its development, they provide the essential knowledge in guiding the development of Ω-Cuff through the clinical study stages.

Product Pipeline

1. Pipeline One: The first product will be Ω-Cuff for the simple treatment of GERD.
2. Pipeline Two: The second product will be Ω-Support for the simple, easy and safe treatment of SUI (stress urinary incontinence in women). The product is designed to avoid issues and complications faced by slings which garnished significant negative publicity, FDA warning, and $billions in litigation settlements.
3. Pipeline Three: The third product could be a device to treat bowel sphincter, a condition which greatly affects the sufferer’s quality of life.